HUE055473T2 - Difluormetil-aminopiridinek és difluormetil-aminopirimidinek - Google Patents
Difluormetil-aminopiridinek és difluormetil-aminopirimidinekInfo
- Publication number
- HUE055473T2 HUE055473T2 HUE15791315A HUE15791315A HUE055473T2 HU E055473 T2 HUE055473 T2 HU E055473T2 HU E15791315 A HUE15791315 A HU E15791315A HU E15791315 A HUE15791315 A HU E15791315A HU E055473 T2 HUE055473 T2 HU E055473T2
- Authority
- HU
- Hungary
- Prior art keywords
- difluoromethyl
- aminopyrimidines
- aminopyridines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192617 | 2014-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE055473T2 true HUE055473T2 (hu) | 2021-11-29 |
Family
ID=51868133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15791315A HUE055473T2 (hu) | 2014-11-11 | 2015-11-10 | Difluormetil-aminopiridinek és difluormetil-aminopirimidinek |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10640516B2 (hu) |
| EP (1) | EP3218358B1 (hu) |
| JP (1) | JP6689843B2 (hu) |
| KR (1) | KR20170101899A (hu) |
| CN (1) | CN107108644B (hu) |
| AU (1) | AU2015345233B2 (hu) |
| CA (1) | CA2965565C (hu) |
| CY (1) | CY1124444T1 (hu) |
| DK (1) | DK3218358T3 (hu) |
| ES (1) | ES2886008T3 (hu) |
| HR (1) | HRP20211336T1 (hu) |
| HU (1) | HUE055473T2 (hu) |
| IL (1) | IL252216B (hu) |
| MA (1) | MA40933A (hu) |
| MX (1) | MX2017006152A (hu) |
| PH (1) | PH12017500854A1 (hu) |
| PL (1) | PL3218358T3 (hu) |
| PT (1) | PT3218358T (hu) |
| RS (1) | RS62289B1 (hu) |
| RU (1) | RU2712091C2 (hu) |
| SG (1) | SG11201703579UA (hu) |
| SI (1) | SI3218358T1 (hu) |
| WO (1) | WO2016075130A1 (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| MA43169B1 (fr) | 2015-11-06 | 2022-05-31 | Incyte Corp | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma |
| ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
| JP6991158B2 (ja) * | 2016-05-18 | 2022-02-10 | ピクール セラピューティクス アーゲー | 神経障害の治療法 |
| JP7118509B2 (ja) * | 2016-05-18 | 2022-08-16 | トルク アーゲー | 皮膚病変の治療 |
| CA3022758C (en) * | 2016-05-18 | 2024-02-06 | Piqur Therapeutics Ag | Treatment of skin lesions |
| TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| CN107266422A (zh) * | 2017-06-12 | 2017-10-20 | 西安交通大学 | 2‑（5‑嘧啶基）‑4‑吗啉基‑6‑取代均三嗪类化合物及其盐、制备方法和应用 |
| JOP20200086A1 (ar) | 2017-10-18 | 2020-04-30 | Incyte Corp | مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما |
| CN109810100B (zh) * | 2017-11-21 | 2022-03-11 | 中国药科大学 | 含有苯并呋喃的parp-1和pi3k双靶点抑制剂 |
| CN111315384A (zh) * | 2017-11-23 | 2020-06-19 | 皮奎尔治疗公司 | 皮肤病的治疗 |
| US20210299133A1 (en) | 2018-08-07 | 2021-09-30 | Piqur Therapeutics Ag | Treatment of squamous cell carcinoma |
| PE20211815A1 (es) | 2018-09-05 | 2021-09-14 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) |
| CN112047938B (zh) * | 2019-06-06 | 2022-11-22 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
| CN111039874B (zh) * | 2019-12-13 | 2022-11-04 | 南开大学 | 一种2-胺基-4-甲基嘧啶化合物的零废水制备方法 |
| KR20210158019A (ko) | 2020-06-23 | 2021-12-30 | 주식회사 온코빅스 | 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| EP4320110A1 (en) * | 2021-04-09 | 2024-02-14 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1389617B1 (en) * | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| KR101296884B1 (ko) * | 2005-03-11 | 2013-08-14 | 젠야쿠코교가부시키가이샤 | 활성 성분으로서 헤테로시클릭 화합물을 포함하는 면역억제제 및 항암제 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CA2675558A1 (en) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2014090147A1 (zh) * | 2012-12-14 | 2014-06-19 | 上海恒瑞医药有限公司 | 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
-
2015
- 2015-11-09 MA MA040933A patent/MA40933A/fr unknown
- 2015-11-10 AU AU2015345233A patent/AU2015345233B2/en active Active
- 2015-11-10 SI SI201531689T patent/SI3218358T1/sl unknown
- 2015-11-10 CN CN201580070995.1A patent/CN107108644B/zh active Active
- 2015-11-10 RS RS20211075A patent/RS62289B1/sr unknown
- 2015-11-10 JP JP2017525032A patent/JP6689843B2/ja active Active
- 2015-11-10 DK DK15791315.3T patent/DK3218358T3/da active
- 2015-11-10 CA CA2965565A patent/CA2965565C/en active Active
- 2015-11-10 KR KR1020177014605A patent/KR20170101899A/ko unknown
- 2015-11-10 HU HUE15791315A patent/HUE055473T2/hu unknown
- 2015-11-10 PT PT157913153T patent/PT3218358T/pt unknown
- 2015-11-10 EP EP15791315.3A patent/EP3218358B1/en active Active
- 2015-11-10 RU RU2017111265A patent/RU2712091C2/ru active
- 2015-11-10 SG SG11201703579UA patent/SG11201703579UA/en unknown
- 2015-11-10 WO PCT/EP2015/076192 patent/WO2016075130A1/en active Application Filing
- 2015-11-10 MX MX2017006152A patent/MX2017006152A/es unknown
- 2015-11-10 PL PL15791315T patent/PL3218358T3/pl unknown
- 2015-11-10 ES ES15791315T patent/ES2886008T3/es active Active
- 2015-11-10 US US15/525,779 patent/US10640516B2/en active Active - Reinstated
-
2017
- 2017-05-08 PH PH12017500854A patent/PH12017500854A1/en unknown
- 2017-05-10 IL IL252216A patent/IL252216B/en unknown
-
2020
- 2020-03-13 US US16/818,512 patent/US11186591B2/en active Active
-
2021
- 2021-08-18 CY CY20211100740T patent/CY1124444T1/el unknown
- 2021-08-19 HR HRP20211336TT patent/HRP20211336T1/hr unknown
- 2021-10-12 US US17/499,048 patent/US20220153752A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| HK1231471A1 (zh) | -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途 | |
| SI3215147T1 (sl) | Nevroatenuacijske spojine norketamina in postopki | |
| PL3152226T3 (pl) | Modyfikowane cyklopentapeptydy i ich zastosowania | |
| GB201401617D0 (en) | Novel combination and use | |
| SG11201704473WA (en) | New methods and uses | |
| HK1243950A1 (zh) | 新型組合物和用途 | |
| HK1243342A1 (zh) | 化合物和方法 | |
| HK1243077A1 (zh) | 呱啶基吡唑並嘧啶酮及其用途 | |
| GB201416727D0 (en) | Use | |
| IL254241A0 (en) | Etv2 and its uses | |
| GB201416716D0 (en) | Use | |
| GB201419650D0 (en) | Modified heterocyclase | |
| GB201408091D0 (en) | Methods and uses | |
| HK1220676A1 (zh) | 配置件和方法 | |
| GB201416082D0 (en) | Method and uses | |
| GB2545167B (en) | Cloches and use thereof | |
| PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
| GB201416073D0 (en) | Methods and uses | |
| GB201416086D0 (en) | Methods and uses | |
| PT2923578T (pt) | Método para a produção de um produto alimentar | |
| GB201404728D0 (en) | Disc-over incorporating disc-heads and disc-earning | |
| GB201404301D0 (en) | Compounds and combinations | |
| GB201420534D0 (en) | Use | |
| GB201420535D0 (en) | Use |